Psoriatic Arthritis

The U.S. FDA has approved to expand the indication for golimumab (SIMPONI ARIA, Janssen Pharmaceutical Companies of Johnson & Johnson) to include it was a treatment for active psoriatic arthritis (PsA) in pediatric patients 2 years and older.

Guselkumab becomes the first IL-23 inhibitor approved for treatment of psoriatic arthritis by the U.S. Food and Drug Administration (FDA) following positive phase 3 results from two trials investigating the safety and efficacy of the drug.

The U.S. Food and Drug Administration has approved Mylan and Fujifilm Kyowa Kirin Biologics’ adalimumab-fkjp as a biosimilar to AbbVie’s adalimumab for a variety of inflammatory disease including plaque psoriasis and psoriatic arthritis.

AbbVie announces they have filed applications with the U.S. FDA and EMA for the approval of the JAK inhibitor upadacitinib for the treatment of adult active psoriatic arthritis.

A recent study shows promising results for using ultrasound to examine hand tendon and joint inflammation in psoriatic arthritis patients.

This slideshow breaks down important considerations to keep in mind when evaluating psoriasis patient for psoriatic arthritis.

A recent study discovered that body mass index (BMI) and age of disease onset may play a part in the development of hypertension in psoriatic arthritis and psoriasis. Read what researchers found in this article.

Researchers employed the the Citizen Pscientist, an online patient portal developed by the National Psoriasis Foundation, to investigate chronic sleep dysfunction prevalence in psoriasis. Read what they discovered in this article. 

A recent study found that Psoriasis Epidemiology Screening Tool (PEST) may help dermatologists identify which patients need a rheumatology referral. 

According to a recent study, patients with psoriatic arthritis may be at a greater risk for adult hearing loss than individuals without psoriatic arthritis.